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Introduction
Chondroblastoma, first described in 1927 by Kolodny and
further detailed by Codman in 1931 and Lichtensterin and
Jaffer more recently, is a benign ephiphyseal/apophyseal
tumor primarily affecting the long bones.1,2 It consists of
1-2% of all primary bone tumors and 5% of benign bone
tumors.3-5 The male to female ratio is 2:1.3-8 The greater
majority of patients are less than 20 years old.9,10 The bones
most affected are the femur and humerus.5-10 While less
common, chondroblastoma tumors can be found in the
tibia, foot, flat bones, and vertebrae.11,12
One single, specific cytogenetic abnormality that
can lead to chondroblastoma has yet to be described.
However, research looking at cartilage signal molecules is
proving promising. Studies have shown the tumor to be of
mesenchymal cell origin, dedicated to chondrogenic life
cycle via signals from active growth plate pathways, thus
verifying the intricate relationship of chondroblastoma to
the epiphysis.14,15
Grossly, chondroblastoma is a gray-white tumor with
yellowish areas of calcification.2 Microscopically, it has
compact areas of chondroblasts with 1-2 nuclei, few mitotic
figures, and the occasional multinucleated osteoclast like
giant cells.6 The textbook finding of dystrophic calcification
“chicken wire” may also be present. Nearly one third of cases
have secondary aneurysmal bone cysts.6-8,10 Aggressive
and metastatic tumors have been shown to have the same
histology as indolent and solitary tumors.16
Chondroblastomas are classified according to the
Enneking benign tumor classification.23 Clinical
presentation is usually insidious in nature with progression
of pain from mild to significant both locally and in the
adjacent joint.3,4,6,8-10 Patients can present with a soft tissue
mass or pathological fracture though this is uncommon
with highest incidence of this in tumors of the foot. They
usually have decreased range of motion and muscle
wasting.4,6,8-11
Radiographically they are well-defined, eccentric oval
or round lytic lesions of the epiphysis adjacent to an open
growth plate.3 Margins are generally sclerotic and sharp,

sometimes having intralesional mottling with or without
calcification. Most tumors are less than 4cm in size.2,4,6,9
It is common to find surrounding soft tissue and marrow
edema, but rare to find periosteal bone formation.17 While
some epiphyseal lesions will cross the physis and invade
the metaphyseal bone, true metaphyseal and diaphyseal
chondroblastomas are rare but have been described.14,18
CT scan is ideal for identifying the tumors anatomic
limits including distance from the growth plate.11,12
Chondroblastoma is hypointense on T1 MRI and variable
hypo-to hyperintense on T2. MRI is ideal for evaluating the
status of surrounding soft tissue and the extent of marrow
edema.17
The natural history of chondroblastoma has shown
that it does not spontaneously resolve and has not been
shown to respond to medical management.5 The standard
of care at this point is intralesional excision via curretage
and bone graft with care to avoid the growth plate in
skeletally immature individuals.6-12 Excision augmented
with high speed burr, electrocautery, phenol, argon beam,
and cryotherapy are all described appropriate treatments.19
Radiofrequency has been shown to have success with
small tumors (<2 cm) that are away from the joint.20 For
aggressive tumors and recurrences, limb-sparing surgery
and endoprosthetic reconstruction are now options.4,10 Due
to late recurrence and possibility of lung metastases, most
recommend an annual follow up for at least 5 years with
chest x-rays at each annual visit.7
The most common complication for chondroblastoma is
recurrence, with studies reporting a 5-40% recurrence rate.
However, the rate of recurrence is not related to one specific
mode of management, tumor size, patient sex, or duration
of follow-up.6,8,9 The most common reason for recurrence is
incomplete resection and biologic aggressiveness.7 Less than
1% of chondroblastomas metastasize. There is no reported
relationship of metastatic lesions to previous surgical or nonsurgical treatment, tumor location, or patient age.16,21,22 The
average time to metastasis is 8 years.16 Common locations
are the lungs, other bones, soft tissue, skin, and liver.16,21
Patients with metastatic chondroblastoma continue to have
long survival rates and no benefit from chemotherapy.
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Case
EG is a 15-year-old female, right hand dominant, who
presented to the pediatric upper extremity clinic in August
of 2013 with a chief complaint of eight months of left
shoulder pain that was constant and exacerbated with use.
Without a history of trauma, her pain was anterior, worse
with overhead activity , decreased range of motion and
significant muscle atrophy. She had mild relief with antiinflammatory medication. She presented with a diagnosis
of rotator cuff tear. Past medical, surgical, birth, and
developmental history were all normal. There is no family
history of cancer.
On physical exam, she was found to have pain with range
of motion and tenderness to palpation at the left proximal
humerus without a palpable mass. Pain significantly limited
her range of motion with forward flexion and abduction at
the left shoulder less than 90 degrees actively and passively.
She had external rotation to neutral. She had noted atrophy
of the left shoulder, arm, and forearm with decreased
strength.
Radiographs of the left shoulder and humerus revealed
a well-circumscribed lucent lesion within the proximal
humeral epiphysis (Figure 1). There was no cortical
disruption noted, but the lesion did extend very near the
glenohumeral articular surface. A 3.0 Tesla MRI revealed a
3.5cm x 3.1cm, x 2.8cm heterogeneous, well-circumscribed
lesion of the epiphysis that invaded the open physis
and extended into the metaphyseal region. There was
noteable marrow and soft tissue edema without axillary
lymphadenopathy and a moderate joint effusion (Figures
2 & 3). CT of the chest was normal without metastatic
lesions to the lungs. Full body bone scan was negative for
multifocal disease.
One week after presentation, the patient had a CTguided core needle biopsy performed by interventional
radiology (IR). Pathology findings were consistent with
chondroblastoma. Three weeks after her initial presentation,
she underwent cryoablation. She experienced temporary
partial relief of her pain from the cryoablation but her
symptoms returned to baseline level in two months.
The patient subsequently underwent two cycles of
radiofrequency ablation three months after her initial
presentation. She again experienced minimal relief and was
taking maximum doses of anti-inflammatory medications.
She was re-evaluated four months after the biopsy and
repeat x-rays, CT, and MRI showed mildly increased
marginal sclerosis as a result of the ablations but the tumor
had increased in size now measuring 3.6cm x 3.5cm x
3.2cm and was very near the articular surface with more
reactive soft tissue and marrow edema. There were also
axillary reactive lymph nodes present.
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Figure 1: AP and Lateral radiographs of left shoulder showing a wellcicrumscribed lucent lesion with intralesional mottling and extension
into the open physis and articular surface.

Figure 2 (left): Axial MRI T1 post-contrast showing lesion measuring
3.5cm x 3.1 cm. There is noteable associated soft tissue and marrow
edema with a moderate joint effusion.
Figure 3 (right): Parasagittal coronal MRI T2 showing proximal marrow
edema while also highlighting the intricate relationship of the lesion to
the open physis.

Figure 4: AP (A) and Lateral (B) radiographs of left shoulder after
curettage and bone grafting. The white material on the x-ray is the bone
graft.

On month 7 from presentation, she underwent
intralesional curettage and grafting of the proximal
humerus with bone graft substitute of calcium phosphate
and calcium sulfate.24 The deltopectoral approach was used
and an anterior cortical window was created. Curettage was
done using a high-speed burr with hydrogen peroxide for
irrigation. Meticulous care was used to avoid the articular
surface. (Figure 4)
Intraoperative pathology results show no cytogenetic
abnormalties on genotyping with classic microscopic
features of chondroblastoma (including molecular marker
S-100 and DOG-1 +) in addition to hypocellular fibrosis

operative x-rays. This potentially does place the patient at
increased risk for recurrence. The amount of symptom relief
the patient experienced is promising. She will be followed
closely in the post-operative period and then annually for at
least 5 years. A follow-up case report is planned, particularly
looking at recurrence, residual shoulder dysfunction, and
maintenance of the glenohumeral joint surface.

*
*

Figure 5: Slide micrograph image of chondroblastoma tissue
biopsy showing area of necrosis after cryoablation (yellow star) and
multinucleated pathological cell (black star).

and reactive and new-bone osteoid matrix. Her histology
showed areas of necrosis from the cryoablation and
pathological multinucleated cells. (Figure 5)
At her most recent follow-up two weeks post-operative,
she had significant decrease from her baseline level of pain.
She was showing increased strength with good effort. She
had the same limited range of motion but minimal pain
through the range.

Discussion
This patient represents a typical presentation of
chondroblastoma. It was explained to the patient and
her family at the time of presentation that intralesional
curettage and bone graft would be the definitive treatment. A
big concern for the patient was finishing out her school year
before undergoing surgery and getting her pain controlled.
Of concern to the surgeons was the proximity of the tumor
to the articular surface of the humerus. Thus, in an effort to
help sustain the articular surface, decrease the patient’s pain,
and to hopefully buy her some time until the school year was
completed, cryoablation was done. Given the patient had
some relief but her pain returned, radiofrequency ablation
was attempted. Repeat imaging after both procedures were
completed showed the tumor had increased in size. These
interventions were not as successful as we had hoped, but
the team was aware prior to the intervention that studies
weren’t reporting much success with tumors the size of the
patient’s in terms of decreasing size or symptom relief. The
post-operative pathology showing hypocellular fibrosis
indicates, however, that there were changes to the tumor as
a result of the ablations.
In an effort to maintain the articular surface of the
proximal humerus, the most superior aspect of the tumor
was not entirely excised and this is evident on post-
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